



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/172162/>

Version: Accepted Version

Article:

Arnold, J, Winthrop, K and Emery, P (2021) COVID-19 vaccination and antirheumatic therapy. *Rheumatology*. keab223. ISSN: 1462-0324

<https://doi.org/10.1093/rheumatology/keab223>

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. This is an author produced version of an article published in *Rheumatology*. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Journal

Rheumatology

Article Type

Review

Title

COVID-19 vaccination and antirheumatic therapy

Authors

Dr Jack Arnold¹ MBBS, MRCP

Professor Kevin Winthrop² MD, MPH

Professor Paul Emery^{1,3} MA MD, FMedSci

Affiliations

1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK
2. Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA
3. NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Correspondence

Professor Paul Emery

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds,
Chapel Allerton Hospital,
Chapeltown Road,
Leeds, LS7 4SA
United Kingdom
Email: p.emery@leeds.ac.uk

Abstract

The COVID-19 vaccination will be the largest vaccination programme in the history of the NHS. Patients on immunosuppressive therapy will be amongst the earliest to be vaccinated. Some evidence indicates immunosuppressive therapy inhibits humoral response to the influenza, pneumococcal and hepatitis B vaccines. The degree to which this will translate to impaired COVID-19 vaccine responses is unclear. Other evidence suggests withholding methotrexate for two weeks post vaccination may improve responses. Rituximab has been shown to impair humoral responses for 6 months or longer post administration. Decisions on withholding or interrupting immunosuppressive therapy around COVID-19 vaccination will need to be made prior to the availability of data on specific COVID-19 vaccine response in these patients. With this in mind, this article outlines the existing data on the effect of antirheumatic therapy on vaccine responses in patients with inflammatory arthritis and formulates a possible pragmatic management strategy for COVID-19 vaccination.

Abstract – 149/150 words

Key Words: COVID-19, Vaccine, Biologics, DMARDs, Rituximab, Methotrexate

Key messages

- Existing work on vaccine response in DMARDs is an imperfect surrogate for COVID-19 vaccine response.
- Methotrexate may impair humoral response; rituximab likely impairs humoral response for 6 months or longer.
- Consider risk stratifying rituximab treated patients and delaying/postponing therapy if appropriate before COVID-19 vaccination.

Introduction

The aim of this viewpoint article is to outline the existing data on the effect of antirheumatic therapy on vaccine responses in patients with inflammatory arthritis, and to formulate a possible pragmatic strategy for the management of therapies in these patients in the context of prospective COVID-19 vaccination. But primarily we aim to facilitate an informed discussion between clinicians and patients in response to issues raised by these data.

COVID-19 needs little introduction, and the 3 effective vaccines produced by Pfizer (mRNA vector), Moderna (mRNA vector) and AstraZeneca (chimpanzee adenovirus vector ChAdOx-1) have provided a potential exit strategy. The COVID-19 vaccine rollout will be the largest mass vaccination programme in the history of the NHS.

Vaccinations exert their protective effect by stimulating both humoral and cellular immune responses. The relative importance of humoral and cellular immunity in conferring protection from infection varies with each infective organism(1). B-cell responses are better represented in the literature due to their ease of antibody measurement and the lack of a clear immune correlate of protection for T-cell driven responses. Nevertheless it is worth noting that emerging evidence suggests a strong role for T-cell mediated immunity in COVID-19 infection(2,3).

Immunosuppressive therapy such as the DMARDs, used to treat most of our patients, may impair vaccine responses. Existing data on this topic largely focus on influenza, pneumococcal and tetanus vaccines. There is a small amount of data also available on the Zostavax vaccine. Whether these data can be extrapolated to provide guidance for vaccination strategies in COVID-19 remains uncertain. Patients on immunosuppressive therapy are being prioritised for vaccination, so management decisions will need to be made

prior any additional COVID-19 data being available. Caveats when assessing the literature are noted below in figure 1.

Figure 1: Caveats when assessing the literature concerning the effect of DMARDs/Biologics on vaccine response

<u>Caveats when assessing the literature</u>
<ul style="list-style-type: none">• Most literature focuses on influenza or pneumococcal vaccine responses, with a smaller number of studies evaluating tetanus/ HBV vaccines. The validity of extrapolating these studies to COVID-19 vaccination using novel (e.g. mRNA) vaccine platforms is uncertain.
<ul style="list-style-type: none">• Most studies assess only humoral responses to vaccination with limited data on T cell responses which may be more important in conferring viral immunity.
<ul style="list-style-type: none">• The degree to which reduced antibody titres on vaccination correlate with impairment of immunity to COVID-19 is uncertain.
<ul style="list-style-type: none">• T-cell mediated immunity is likely to be important in COVID-19 vaccination based on data to date. However currently there is no known immune correlate of protection identified.

Impact of antirheumatic therapy on vaccine response

Figure 2 below summarises a review of the literature on the impact of anti-rheumatic therapy on vaccine response. Further discussion is under the relevant headings.

Figure 2: Summary of existing evidence on vaccine efficacy alongside DMARD/biologic therapy

Drug	Findings	Interpretation/Advice on Management
Corticosteroids	<ul style="list-style-type: none"> Doses >10mg prednisolone OD associated with impaired humoral immunity(1–5). Doses <10mg prednisolone OD not shown to impair humoral response. Doses >10mg prednisolone OD associated with poorer outcomes in hospitalised COVID-19 patients(6). 	<ul style="list-style-type: none"> Channelling bias present, as patients on steroid therapy generally sicker. Could consider tapering prednisolone to <10mg OD where possible, likely already standard practice
csDMARDs (Not MTX)	<ul style="list-style-type: none"> Small reduction in vaccine induced antibody levels but maintained seroprotective titres(7–11). Most MMF data from transplant patients (11). 	<ul style="list-style-type: none"> Continue therapy
Methotrexate (alone or in combination)	<ul style="list-style-type: none"> Methotrexate may impair humoral response to pneumococcal and influenza vaccines(12–14). Limited data suggesting an improved humoral responses to influenza vaccine if MTX held for 2 weeks post vaccination(13). Withholding for >2 weeks associated with increased flare risk without further improvement in vaccine response(13). 	<ul style="list-style-type: none"> Some evidence to hold for 2 weeks post vaccination. Limited generalisability and may increase flare risk. Need further data.
Anti TNF	<ul style="list-style-type: none"> Quantitative but not significant impairment of humoral vaccine response with influenza (1,5,7,15) but limited evaluation. Some impairment of response to HBV vaccine demonstrated(16,17). 	<ul style="list-style-type: none"> Continue therapy
Anti IL6	<ul style="list-style-type: none"> No significant impairment of humoral vaccine response(18,19). 	<ul style="list-style-type: none"> Continue therapy
Abatacept	<ul style="list-style-type: none"> Conflicting data, shown to impair influenza vaccine response in 2011(20). Normal results for S/C preparation assessing influenza and pneumococcal vaccine response(21). Small study showed impairment of PCV-7 response (22). 	<ul style="list-style-type: none"> Conflicting evidence but no clear evidence to discontinue. Limited evaluation of data no control group on two studies(20,21). Only 17 abatacept treated patients in other study(22). Need further data especially on theoretical effect on Tcell responses
JAK inhibitors	<ul style="list-style-type: none"> Baricitinib treated patients shown to mount effective PCV-13 vaccine response, but less robust tetanus responses (23). T cell responses to the PCV-13 vaccine were preserved in tofacitinib treated patients(24). Tofacitinib did reduce influenza vaccine titres but seroprotective titres were preserved (25). cPPSV-23 seroprotective responses were lower than placebo controls (25). Among present tofacitinib users, discontinuing tofacitinib for one week before and after vaccination had no effect upon the proportion of patients reaching seroprotection (25). Tofacitinib shown to be safe in context of live zoster vaccine, starting tofacitinib 2-3 weeks post vaccination yielded similar humoral and cell-mediated responses to controls(26). 	<ul style="list-style-type: none"> Evidence suggests some diminished humoral responses to influenza and PPSV-23. Biologically plausible that may inhibit mRNA vaccines with a substantial interferon driven response
Anti CD20	<ul style="list-style-type: none"> Shown to impair humoral response to both PPSV-23 and influenza vaccine(3,12,27,28). Effect most pronounced if vaccinated earlier <3mts after rituximab therapy(27,28). Improved vaccine response if vaccinated >6months after RTX therapy(27,28). 	<ul style="list-style-type: none"> Aim to vaccinate before RTX or >6mths post RTX treatment where possible. Could consider postponed therapy in specific cases.

Downloaded from https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keab223/6169010 by University of Leeds user on 15 March 2021

Corticosteroids

Corticosteroids affect vaccine efficacy in a dose dependent manner. Several studies have assessed the impact of corticosteroid therapy on humoral response to the pneumococcal and influenza vaccines(4–8). Doses >10mg prednisolone daily were associated with a degree of impaired humoral immunity in a longitudinal study however lower doses had little impact(5). Steroid doses >10mg daily prednisolone were associated with poorer outcomes in hospitalised patients with COVID-19(9).

csDMARDs

Other than methotrexate there is limited evidence for significant impairment of humoral vaccine responses to other conventional synthetic DMARDs (csDMARDs). Sulfasalazine, hydroxychloroquine, azathioprine, and leflunomide may reduce vaccine-antibody titres but have not been shown to inhibit a seroprotective response to the pneumococcal or influenza vaccines(10–14).

Much of the trial data on mycophenolate is from organ transplant patients. These trials did not assess responses where mycophenolate was withheld, due to the high risk of graft rejection(14). Mycophenolate was shown to reduce antibody titres but not below the threshold for seroprotection.

Methotrexate has been shown to impair humoral response to the pneumococcal and influenza vaccines(15–18). This is unsurprising given its ability (and use) to reduce antibody formation to monoclonal antibodies. Withholding methotrexate around the time of vaccination has been assessed for 4 weeks before influenza vaccination, 2 weeks either side of vaccination and 4 weeks post vaccination (16,18). Holding methotrexate for 4 weeks after immunisation substantially improved vaccine titres. A subsequent study suggested that the critical period for vaccine induced humoral immunity was the 2 week period following vaccination(16,18).

Longer periods of withholding methotrexate were not shown to confer better vaccine responses but were associated with an increased incidence of disease flare. It appears MTX has same impact on vaccination when used in combination with other DMARDs. The same risk benefit assessment is required for a decision on temporary withholding.

TNF inhibition

Several studies have assessed the impact of anti-TNF therapies on pneumococcal and influenza vaccines. There have been no consistent data linking these treatments to significant impairment of the immune response. However, in patients who are taking concurrent methotrexate, responses have been shown to be impaired. While seroprotective responses are typically maintained, vaccine antibody titres may be lower than for matched controls(4,8,10,19). TNF inhibition has also been shown to be safe in the context of the live varicella zoster vaccine(20).

In the context of COVID-19 early registry data has shown anti-TNF therapy to be associated with a decreased odds of hospitalisation due to COVID-19(9).

IL6 inhibitors

Two large Japanese studies have assessed the impact of IL-6 inhibition on influenza and pneumococcal vaccine responses. One showed impaired responses in the IL-6 inhibitor + methotrexate combination treatment arm but no impairment with IL-6 inhibition monotherapy(21). A subsequent study showed no significant impairment in humoral response to the influenza and pneumococcal vaccines at 12 weeks in tocilizumab treated patients(22).

Abatacept

There is some conflict within the existing data. Abatacept was shown to impair response to the H1N1 influenza vaccine in comparison to age matched patients(23). Abatacept was

shown to impair PCV-7 responses in another small volume study with 17 abatacept treated patients enrolled(24). However subsequent work showed no impairment of response to the trivalent influenza and pneumococcal polysaccharide vaccines in patients treated with subcutaneous abatacept at a dose of 125mg weekly(25). Interpretation of data is problematic as the two papers lacked a control group and one study recruited only 17 abatacept treated patients.

JAK inhibitors

JAK inhibition may prove to be problematic in the context of the mRNA COVID-19 vaccines which induce a strong type 1 interferon driven immune response. Theoretically inhibition of this pathway could be associated with a diminished response.

The effect of baricitinib on pneumococcal conjugate and tetanus toxoid vaccine response was assessed and showed that 68% of patients on long term baricitinib mounted seroprotective responses to the pneumococcal vaccine, although tetanus toxoid responses were less durable(26).

One study assessed the impact of tofacitinib (plus MTX in half of cases) on PPSV-23 and influenza vaccine response(27). Here similar proportions of tofacitinib and control patients achieved a satisfactory response to the influenza vaccine, but pneumococcal responses were impaired, particularly when tofacitinib was combined with methotrexate. Temporary discontinuation of tofacitinib therapy for 1-week pre-vaccination until 1 week after – vaccination was not shown to impact on the humoral response.

A recent abstract data from the American College of Rheumatology (ACR) has suggested a satisfactory response to the adjuvant herpes subunit zoster vaccine in JAK-inhibitor treated patients(28). However, one quarter of the JAK-inhibitor treated patients failed to mount any humoral vaccine response at all. Additionally the live zoster vaccine Zostavax has been

shown to be safe and effective in tofacitinib treated patients in a study where similar VZV-specific humoral and cell-mediated responses were seen in controls and patients who started tofacitinib 2-3 weeks after live zoster vaccine administration(29).

Anti-CD20

B-cell depleting therapy has been shown to impair humoral responses to the influenza and pneumococcal vaccines in several studies and a subsequent meta-analysis(6,15,30,31).

Biologically this is consistent with the critical role of B cells in humoral vaccine responses.

In 2008 csDMARD treated patients were compared to csDMARD/rituximab combination therapy patients in the context of the influenza vaccine. Lower antibody titres were identified to all antigens in the combination therapy group and were statistically significant in one case(6). One study assessed influenza vaccine response in early (4-8 weeks) and late (6-10 months) rituximab treated patients(31). Impairment of response was greater in the early rituximab treatment arm. Another study showed general impairment of humoral responses to the influenza vaccine post rituximab therapy, but better humoral responses in the late (>5mths post treatment) rather than early treatment groups(30).

There is some early data suggesting worse outcomes particularly in rituximab treated COVID-19 patients. Case reports have described severe COVID phenotypes in patients treated with rituximab for rheumatological and other B-cell driven disorders(32–34). Early study data has in some cases suggested poorer outcomes in rituximab treated patients who become hospitalised with COVID-19 (35,36). However, it is likely there is a significant channelling bias as rituximab treated patients generally have higher rates of interstitial lung disease and other factors associated with poorer outcomes in COVID-19. Nevertheless, such data are concerning and reinforce the need for judicious use of rituximab for only the most clinically necessary cases during a global pandemic.

Risk stratifying and timing vaccinations

Rheumatology departments require guidance on how to manage DMARD/biologic therapies in the context of mass COVID-19 vaccination and this guidance will evolve with time.


Existing EULAR guidance is available but may not be sufficient in the context of a global pandemic(37) In every case the benefits of reducing medication needs to be weighed against the risk of disease flare, which apart from the obvious disadvantage is known to reduce vaccination effectiveness(38). Key considerations are summarised in figure 3 below.

Figure 3: Therapy considerations when vaccinating against COVID-19

<u>Therapeutic considerations when vaccinating against COVID-19</u>
<p>Where appropriate:</p> <ul style="list-style-type: none">• Avoid vaccination during disease flare• Taper steroid therapy to <10mg prednisolone daily• Consider withholding methotrexate for 2 weeks post vaccination both when used as monotherapy and in combination with other DMARDs. (As two doses of current vaccines are required, this may would need to be done twice).• Avoid vaccinating ideally for 6 months post rituximab; if vaccination is imminent consider delaying RTX infusion if no risk of organ failure/disease flare. If a patient is unlikely to receive vaccination for 6 months there is an argument for expediting RTX treatment.• If there is insufficient time to alter or amend DMARD/biologic treatment, then we would recommend vaccination and reassessment of vaccine response at a later date.

A summary of the possible challenges specific to rituximab is depicted below in figure 4.

Figure 4: Factors influencing rituximab treatment decisions



For methotrexate withholding treatment for 2 weeks following each vaccine dose may help improve humoral response. This is speculative in the context of novel vaccine techniques but could be considered in patients on MTX (and perhaps JAKi) at low to moderate risk of disease flare. Where a flare occurs, they would require treatment and high doses of prednisolone should be avoided where possible due to its possible effects on vaccine responses and COVID-19 morbidity. However, once again, it is important to stress that the priority is to proceed with vaccination, and modification of therapy should not delay this.

The situation with JAK-inhibitors is unknown, as unlike the MTX study they have only been withheld for 1-week post vaccination so far. Some data from work on the influenza and PPSV-23 vaccines and the strong type 1 interferon response generated by the mRNA vaccines suggests that withholding JAK-inhibitors might improve COVID-19 vaccine responses, but this is speculative. Whilst for abatacept, the data are conflicting and given its mode of action which could inhibit T cell responses, treatment guidance urgently requires further evidence.

In all cases any decision to delay treatment should be the result of an informed discussion by each patient and physician on a case-by-case basis.

Further work

Additional COVID-19 specific data will be critical in producing more evidence-based recommendations. Quantification of COVID-19 vaccine antibody titres, evidence on T-cell immunity and additional work on the impact of booster vaccinations will all be relevant, and there is ongoing work in Leeds collecting such data with and without medication modification. COVID-19 is likely to be a long-term issue, and the data from such a study should be of value, for advice on protection and optimal future vaccination strategy.

Funding

No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.

Acknowledgements

This report presents independent research supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. PE is director of Leeds NIHR BRC.

Conflicts of interest

JA has no conflicts of interest. KW has received consulting fees from Pfizer, AbbVie, Union Chimique Belge (UCB), Eli Lilly & Company, Galapagos, GlaxoSmithKline (GSK), Roche, Gilead, BMS, Regeneron, Sanofi, AstraZeneca and Novartis. He has also received research grants paid to his employer from BMS and Pfizer. PE has provided expert advice to Pfizer,

Abbvie, Amgen, MSD, Roche, Sanofi, BMS, Novartis, Lilly, Gilead, Samsung, Celltrion and received grants paid to his employer from Abbvie, BMS and Samsung

Data availability statement

No new data were generated or analysed in support of this review.

References

1. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments [Internet]. Vol. 21, Nature Reviews Immunology. Nature Research; 2020 [cited 2021 Feb 10]. p. 83–100. Available from: <https://doi.org/10.1038/>
2. Karlsson AC, Humbert M, Buggert M. The known unknowns of T cell immunity to COVID-19 [Internet]. Vol. 5, Science Immunology. American Association for the Advancement of Science; 2020 [cited 2021 Feb 10]. p. 8063. Available from: <http://immunology.sciencemag.org/>
3. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature [Internet]. 2020 Aug 20 [cited 2021 Feb 10];584(7821):457–62. Available from: <https://doi.org/10.1038/s41586-020-2550-z>
4. Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2010 Jun 1;39(6):442–7.
5. Fischer L, Gerstel PF, Poncet A, Siegrist CA, Laffitte E, Gabay C, et al. Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for

- inflammatory diseases - A longitudinal study. *Arthritis Res Ther* [Internet]. 2015 Jun 6 [cited 2020 Dec 14];17(1):151. Available from: <http://arthritis-research.com/content/17/1/151>
6. Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, et al. Vaccination against influenza in patients with rheumatoid arthritis: The effect of rituximab on the humoral response. *Ann Rheum Dis*. 2008;67(7):937–41.
 7. Coulson E, Saravanan V, Hamilton J, Long KS, Morgan L, Heycock C, et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. *Ann Rheum Dis* [Internet]. 2011 Jul [cited 2020 Dec 14];70(7):1289–91. Available from: <https://pubmed.ncbi.nlm.nih.gov/21515601/>
 8. Ben Nessib D, Fazaa A, Miladi S, Sellami M, Ouenniche K, Souabni L, et al. Do immunosuppressive agents hamper the vaccination response in patients with rheumatic diseases? A review of the literature. *Therapies* [Internet]. 2020; Available from: <https://doi.org/10.1016/j.therap.2020.08.002>
 9. Gianfrancesco M, Hyrich KL, Hyrich KL, Al-Adely S, Al-Adely S, Carmona L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis* [Internet]. 2020 Jul 1 [cited 2020 Nov 18];79(7):859–66. Available from: <http://dx.doi.org/10.1136/annrheumdis-2020-217871>
 10. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: The effect of disease modifying drugs, including TNF α blockers. *Ann Rheum Dis* [Internet]. 2006 Feb 1 [cited 2020 Nov 17];65(2):191–4. Available from: <https://ard.bmj.com/content/65/2/191>
 11. Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J, et al. Protective effect

- of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study. *Rheumatology* [Internet]. 2012 Apr 1 [cited 2020 Dec 15];51(4):695–700. Available from: <https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/ker389>
12. Franca ILA, Ribeiro ACM, Aikawa NE, Saad CGS, Moraes JCB, Goldstein-Schainberg C, et al. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. *Rheumatology* [Internet]. 2012 Nov 1 [cited 2020 Dec 15];51(11):2091–8. Available from: <https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/kes202>
 13. Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A prospective, open-label, parallel-cohort, single-center study. *Arthritis Rheum* [Internet]. 2011 Jun 1 [cited 2020 Dec 15];63(6):1486–96. Available from: <http://doi.wiley.com/10.1002/art.30325>
 14. Keshtkar-Jahromi M, Argani H, Rahnavardi M, Mirchi E, Atabak S, Tara SA, et al. Antibody response to influenza immunization in kidney transplant recipients receiving either azathioprine or mycophenolate: A controlled trial. *Am J Nephrol* [Internet]. 2008 Jun [cited 2020 Dec 14];28(4):654–60. Available from: <https://pubmed.ncbi.nlm.nih.gov/18322360/>
 15. Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α , and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis [Internet]. Vol. 66, *Arthritis Care and Research*. John Wiley and Sons Inc.; 2014 [cited

2020 Nov 17]. p. 1016–26. Available from:

<https://onlinelibrary.wiley.com/doi/full/10.1002/acr.22246>

16. Park JK, Choi Y, Winthrop KL, Song YW, Lee EB. Optimal time between the last methotrexate administration and seasonal influenza vaccination in rheumatoid arthritis: Post hoc analysis of a randomised clinical trial [Internet]. Vol. 78, *Annals of the Rheumatic Diseases*. BMJ Publishing Group; 2019 [cited 2020 Nov 17]. p. 1283–4. Available from: <https://ard.bmj.com/content/78/9/1283>
17. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. *Rheumatology* [Internet]. 2006 Jan 1 [cited 2020 Nov 17];45(1):106–11. Available from: www.DAS-score.nl
18. Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: A randomised clinical trial. *Ann Rheum Dis* [Internet]. 2018 Jun 1 [cited 2020 Dec 16];77(6):898–904. Available from: <http://ard.bmj.com/>
19. Kivitz AJ, Schechtman J, Texter M, Fichtner A, De Longueville M, Chartash EK. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: Results from a single-blind randomized phase IV trial. *J Rheumatol* [Internet]. 2014 Apr 1 [cited 2020 Nov 17];41(4):648–57. Available from: www.jrheum.org
20. Curtis J, Bridges SL, Cofield SS, Bassler J, Ford T, Lindsey S, et al. Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients. *Arthritis Rheumatol* [Internet]. 2019 [cited 2020 Dec 20];71.

- Available from: <https://acrabstracts.org/abstract/results-from-a-randomized-controlled-trial-of-the-safety-of-the-live-varicella-vaccine-in-tnf-treated-patients/>
21. Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. *Ann Rheum Dis* [Internet]. 2012 Dec 1 [cited 2020 Nov 17];71(12):2006–10. Available from: <http://ard.bmj.com/>
 22. Tsuru T, Terao K, Murakami M, Matsutani T, Suzaki M, Amamoto T, et al. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. *Mod Rheumatol* [Internet]. 2014 [cited 2020 Nov 17];24(3):511–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/24252023/>
 23. Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA, et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. *Arthritis Care Res (Hoboken)* [Internet]. 2013 Mar 1 [cited 2020 Nov 24];65(3):476–80. Available from: <http://doi.wiley.com/10.1002/acr.21838>
 24. Crnkic Kapetanovic M, Saxne T, Jönsson G, Truedsson L, Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. *Arthritis Res Ther* [Internet]. 2013 Oct 30 [cited 2020 Dec 16];15(5). Available from: <https://pubmed.ncbi.nlm.nih.gov/24286269/>
 25. Alten R, Bingham CO, Cohen SB, Curtis JR, Kelly S, Wong D, et al. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. *BMC Musculoskelet Disord* [Internet]. 2016 Dec 26

- [cited 2020 Nov 12];17(1):231. Available from:
<https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-016-1082-z>
26. Winthrop KL, Bingham CO, Komocsar WJ, Bradley J, Issa M, Klar R, et al. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: Results from a long-term extension trial substudy. *Arthritis Res Ther* [Internet]. 2019 Apr 18 [cited 2020 Nov 17];21(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/30999933/>
 27. Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. *Ann Rheum Dis* [Internet]. 2016 Apr 1 [cited 2020 Nov 17];75(4):687–95. Available from: <http://ard.bmj.com/>
 28. Källmark H, Gullstrand B, Nagel J, Einarsson J, Jönsson G, Kahn F, et al. Immunogenicity of Adjuvanted Herpes Zoster Subunit Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors and Controls: Preliminary Results - ACR Meeting Abstracts [Internet]. ACR Convergence 2020. 2020 [cited 2020 Dec 14]. p. Abstract Number: 1997. Available from: <https://acrabstracts.org/abstract/immunogenicity-of-adjuvanted-herpes-zoster-subunit-vaccine-in-rheumatoid-arthritis-patients-treated-with-janus-kinase-inhibitors-and-controls-preliminary-results/>
 29. Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, et al. The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. *Arthritis Rheumatol* [Internet]. 2017 Oct 1 [cited 2020 Dec 20];69(10):1969–77. Available

- from: <http://doi.wiley.com/10.1002/art.40187>
30. Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. *Vaccine* [Internet]. 2011;29(8):1643–8. Available from: <http://dx.doi.org/10.1016/j.vaccine.2010.12.072>
 31. Van Assen S, Holvast A, Benne CA, Posthumus MD, Van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. *Arthritis Rheum* [Internet]. 2010 Jan 1 [cited 2020 Nov 22];62(1):75–81. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/art.25033>
 32. Tepasse P, Hafezi W, Lutz M, Kühn J, Wilms C, Wiewrodt R, et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. *Br J Haematol* [Internet]. 2020 Jul 22 [cited 2020 Dec 14];190(2):185–8. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.16896>
 33. Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ, et al. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: Lessons from a case with severe pneumonia [Internet]. *Annals of the Rheumatic Diseases*. BMJ Publishing Group; 2020 [cited 2020 Dec 14]. Available from: <https://pubmed.ncbi.nlm.nih.gov/32312768/>
 34. Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab [Internet]. *Annals of the Rheumatic Diseases*. BMJ Publishing Group; 2020 [cited 2020 Dec 14]. Available from: <https://www>.
 35. Antía García-Fernández, Fernando López-Gutiérrez, Jesús Loarce-Martos, Ivan Del

- Bosque-Granero, Laura Calvo-Sanz, Boris Blanco-Cáceres, Cristina Pijoan-Moratalla, Lourdes Villalobos-Sánchez JB-C and MV. Cohort of Rheumatic Patients Treated with Rituximab and COVID-19: Does Rituximab Treatment Increases the Severity of SARS-COV2 Infection? - ACR Meeting Abstracts [Internet]. ACR Convergence 2020. 2020 [cited 2020 Dec 14]. p. Abstract number 0641. Available from: <https://acrabstracts.org/abstract/cohort-of-rheumatic-patients-treated-with-rituximab-and-covid-19-does-rituximab-treatment-increases-the-severity-of-sars-cov2-infection/>
36. Nuño L, Novella Navarro M, Bonilla G, Franco-Gómez K, Aguado P, Peiteado D, et al. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. *Ann Rheum Dis* [Internet]. 2020 Jun 30 [cited 2020 Nov 18];79(12):annrheumdis-2020-218054. Available from: <https://www.annrheumdis-2020-218054>.
37. Van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Ann Rheum Dis* [Internet]. 2011 Mar 1 [cited 2021 Feb 9];70(3):414–22. Available from: <http://www.clinicaltrials.gov/>
38. Emery P, Panayi G, Symmons D, Brown G. Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: The role of protein energy malnutrition. *Ann Rheum Dis* [Internet]. 1984 [cited 2021 Feb 10];43(3):430–4. Available from: <https://pubmed.ncbi.nlm.nih.gov/6430250/>